What Are GLP-1 Peptides and Why Is Everyone Talking About Them?

Your body already makes GLP-1. It’s a 30-amino-acid peptide hormone produced by L-cells in your small intestine every time you eat. The full name is glucagon-like peptide-1, and its job is straightforward: tell your brain you’re full and tell your pancreas to release insulin. You’ve had this system running since birth. The reason it’s suddenly everywhere in 2025 and 2026 is that pharmaceutical companies figured out how to make synthetic versions that last days instead of minutes, and the weight loss results from clinical trials were so dramatic that they changed the entire conversation around obesity treatment.

There’s a problem with how most of this gets discussed online, though. GLP-1 medications get lumped in with “peptides” as if that’s some sketchy category of supplements you buy from a guy on Reddit. Or they get treated as miracle drugs with no biological basis worth understanding. Both of those takes are wrong. I want to actually talk about what peptides are, where GLP-1 fits, what these medications do at a molecular level, and why the line between “peptide” and “drug” is blurrier than most people realize.

Peptides are not a fringe thing

A peptide is a short chain of amino acids. That’s really all it is. If a chain has fewer than about 50 amino acids, biochemists call it a peptide. Longer than that, it’s a protein. Insulin is a peptide. Oxytocin is a peptide. The endorphins that hit after a long run are peptides. Your body produces hundreds of them, and they control everything from hunger to sleep to inflammation to wound healing.

The word “peptide” picked up a bad reputation because compounds like BPC-157 and various growth hormone secretagogues got popular in biohacking circles before they had FDA-approved uses. People were buying lyophilized powder from research chemical suppliers, reconstituting it in their kitchens, and injecting based on forum advice. That gave the entire category an underground reputation that has nothing to do with the actual science.

GLP-1 is a peptide in the most basic biochemical sense. Thirty amino acids. Your gut makes it. It binds to a specific receptor on cells in your pancreas, brain, stomach, and other organs. When researchers at Novo Nordisk and Eli Lilly created semaglutide and tirzepatide, they didn’t invent some new class of molecule. They took a peptide your body already produces and modified it so it could survive in the bloodstream long enough to actually do something sustained.

Here’s why native GLP-1 doesn’t cut it on its own: an enzyme called DPP-4 breaks it down within about two minutes of release. That’s why you don’t feel full forever after eating a handful of almonds. Semaglutide gets around this by attaching a fatty acid chain to the peptide that lets it bind to albumin in your blood, which shields it from DPP-4 degradation. The result is a half-life of roughly 7 days instead of 2 minutes. Same receptor. Same signaling pathway. Radically different duration.

What these medications actually do once they’re in your system

The headline is always “you feel less hungry,” and that’s true, but the biology underneath is more interesting than the headline.

Start with the pancreas. GLP-1 receptor activation stimulates glucose-dependent insulin secretion. “Glucose-dependent” matters here. Unlike older diabetes medications that force insulin release regardless of blood sugar levels (which can tank you into hypoglycemia), GLP-1 agonists only boost insulin when glucose is actually elevated. They also suppress glucagon, the hormone that raises blood sugar. This dual action is why semaglutide was originally approved for type 2 diabetes as Ozempic before it became a weight loss phenomenon as Wegovy.

In the brain, GLP-1 receptors sit in the hypothalamus and brainstem, areas that regulate appetite and satiety. When semaglutide or tirzepatide activates these receptors, it dials down what researchers call “food reward” signaling. People on these medications don’t just eat less because they feel full faster. They report that food becomes less interesting. The constant mental loop of thinking about what to eat next gets quieter. This is also why there’s early research interest in whether GLP-1 agonists could help with alcohol use disorder and other compulsive behaviors. The data is preliminary, but the mechanistic rationale is real.

Then there’s the stomach. GLP-1 slows gastric emptying, so food sits there longer. That contributes to fullness but also explains the most common side effect: nausea, especially during the first few weeks of dose titration. It’s not a random side effect. It’s a direct consequence of the mechanism of action. Most people find it manageable and temporary.

The cardiovascular angle surprised a lot of people. The SELECT trial, published in the New England Journal of Medicine in 2023, showed a 20% reduction in major adverse cardiovascular events among people with obesity who took semaglutide. Even people without diabetes saw the benefit. That shifted the entire framing from “weight loss drug” to “cardiometabolic drug,” and it’s part of why insurance coverage arguments are starting to change.

Semaglutide vs. tirzepatide

Both are GLP-1 receptor agonists, but tirzepatide also hits the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone involved in insulin secretion and energy metabolism. Also a peptide, since we’re keeping track.

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, showed tirzepatide at its highest dose (15 mg) producing an average weight loss of 22.5% of body weight at 72 weeks. The STEP 1 trial for semaglutide showed 14.9% at 68 weeks. You can’t perfectly compare those numbers because the trials were designed differently, but the broad consensus is that tirzepatide produces somewhat more weight loss on average.

Does that mean tirzepatide is “better”? Not necessarily. Tolerability varies person to person. So does insurance coverage, prior medication history, and how a specific patient responds. They work on overlapping but distinct receptor pathways, and I’ve talked to physicians who’ve had patients do great on semaglutide after not responding well to tirzepatide, and vice versa.

What both medications share is the basic architecture: modified peptides, delivered by weekly subcutaneous injection, activating receptors your body already has for hormones your body already makes.

The compounding question

This is where it gets practical. Brand-name Wegovy and Zepbound have been in and out of shortage since their FDA approvals. Demand has massively outpaced supply. During declared shortages, compounding pharmacies were legally permitted to produce compounded versions under FDA enforcement discretion.

Compounding isn’t new or unusual. It’s a pharmacy preparing a medication tailored to a patient’s needs. Your local pharmacy does some form of compounding every day. But there’s a spectrum of facilities, and the differences matter more than most people realize.

A 503A pharmacy is a traditional compounding pharmacy making medications on an individual prescription basis, usually serving its local area. A 503B outsourcing facility operates under more direct FDA oversight and follows cGMP (current Good Manufacturing Practice) standards that are similar to what large pharmaceutical manufacturers follow. The testing, quality control, and regulatory scrutiny at a 503B facility is substantially more rigorous than at a 503A.

If you’re looking at compounded GLP-1 medications, sourcing matters more than price. A physician-supervised telehealth platform that sources from 503B pharmacies is a fundamentally different thing than buying a vial from an unregulated source online. The active compound may be the same, but the manufacturing standards, purity testing, and medical oversight are not even in the same ballpark.

This is actually where understanding peptide chemistry becomes practically useful. Peptides are finicky molecules. They degrade if stored wrong, lose potency without adequate quality control, and can become contaminated in facilities without proper sterile technique. The difference between a peptide from a cGMP-compliant 503B pharmacy and one from an unregulated source isn’t regulatory theater. It’s the difference between knowing what’s actually in the vial and hoping for the best.

Why “are peptides safe?” is the wrong question

I see this question constantly online, and it drives me a little crazy because it’s basically unanswerable. It’s like asking “are chemicals safe?” Peptides are a class of molecules. Insulin is a peptide. Botulinum toxin comes from a peptide. The safety profile depends entirely on which peptide, what dose, how it was manufactured, and whether a doctor is involved.

For GLP-1 receptor agonists specifically, the safety data is about as extensive as it gets in modern medicine. Semaglutide has been through the STEP trial program (STEP 1 through 5 and counting), the SUSTAIN trials for diabetes, and the SELECT cardiovascular outcomes trial. Tirzepatide has SURMOUNT and SURPASS. We’re talking about tens of thousands of patients in randomized controlled trials, many running 68 weeks or longer.

The common side effects are GI-related: nausea, vomiting, diarrhea, constipation. Usually worst during dose escalation, usually improve with time. There are labeled warnings about thyroid C-cell tumors (based on rodent studies, not confirmed in humans), pancreatitis, and gallbladder disease. These are real things a prescribing physician should talk through with any patient.

But framing the safety question around “peptides” as a category conflates FDA-studied medications with research chemicals someone ordered from an overseas website. It does a genuine disservice to people trying to figure out what’s actually safe and what isn’t.

The weight regain problem

“You’ll just gain it all back when you stop.” I hear this constantly. And the data is real: the STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight over the following year.

But think about what that actually means for a second. If someone with high blood pressure stops their medication, their blood pressure goes back up. Nobody says “see, the drug didn’t work.” Obesity is, for many people, a chronic condition driven by hormonal and neurological factors that don’t just resolve because you lost weight for a while. The “you’ll gain it back” framing treats weight as a character issue rather than a physiological one, and the clinical data doesn’t support that framing at all.

That doesn’t mean everyone needs to take GLP-1 medications forever. Some people use them to get to a target weight and maintain from there with diet and exercise changes. Some stay on a lower maintenance dose long-term. Some cycle. The right approach depends on the patient and their doctor, not on somebody’s Twitter take about willpower.

What the regain data actually tells us is that GLP-1 signaling plays an ongoing role in weight regulation. Which is exactly what you’d expect if you understood the biology. Your body makes GLP-1 continuously, not as a one-time event. A drug that mimics it will work for as long as you take it. That’s not a design flaw. That’s just how hormones work.

Where this is heading

The pipeline is stacked. Oral semaglutide (no more needles) is already available for diabetes and being studied for obesity at higher doses. Novo Nordisk’s amycretin, a GLP-1/amylin combo, showed 25% weight loss in early phase trials. Eli Lilly’s retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors all at once, and it showed up to 24% weight loss at 48 weeks in phase 2.

There’s also growing research interest beyond metabolism: MASH (the liver disease formerly called NASH), sleep apnea, chronic kidney disease, and addiction. The GLP-1 receptor turns out to be expressed in a lot of tissue, and activating it has downstream effects researchers are still cataloging.

For anyone trying to figure out their options right now, here’s where I’d land: GLP-1 medications are well-studied, peptide-based therapies with strong clinical evidence behind them. They work by mimicking a hormone your body already makes. They’re not supplements. They’re not research chemicals. They’re prescription medications that should be prescribed by a licensed physician, sourced from a real pharmacy, and understood as medical treatment for a medical condition.

GLP-1 is a peptide. Semaglutide and tirzepatide are modified versions of that peptide. They work because they slot into a receptor system that evolution spent a very long time building. The conversation will keep evolving as more data comes in and new compounds hit the market. But the underlying biology isn’t going anywhere. Your gut makes GLP-1. These drugs mimic it. And for millions of people, that’s turning out to be one of the most effective medical interventions we’ve had for obesity.